PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate lipid and glucose metabolism and cellular differentiation. PPAR-alpha and PPAR-gamma are both expressed in human macrophages where they exert anti-inflammatory effects. The activation of PPAR-alpha may promote foam-cell formation by inducing expression of the macrophage scavenger receptor CD36. This prompted us to investigate the influence of different PPAR-activators on cholesterol metabolism and foam-cell formation of human primary and THP-1 macrophages. Here we show that PPAR-alpha and PPAR-gamma activators do not influence acetylated low density lipoprotein-induced foam-cell formation of human macrophages. In contrast, PPAR-alpha and PPAR-gamma activators induce the expression of the gene encoding ABCA1, a transporter that controls apoAI-mediated cholesterol efflux from macrophages. These effects are likely due to enhanced expression of liver-x-receptor alpha, an oxysterol-activated nuclear receptor which induces ABCA1-promoter transcription. Moreover, PPAR-alpha and PPAR-gamma activators increase apoAI-induced cholesterol efflux from normal macrophages. In contrast, PPAR-alpha or PPAR-gamma activation does not influence cholesterol efflux from macrophages isolated from patients with Tangier disease, which is due to a genetic defect in ABCA1. Here we identify a regulatory role for PPAR-alpha and PPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This mechanism is pivotal in controlling intracellular lipid content and serves as a primary “gatekeeper” for reverse cholesterol transport in cells [23].”
From miR-223 accelerates lipid droplets clearance in microglia following spinal cord injury by upregulating ABCA1 (2024) · cites this paper as [23]
In the citing paper
“The activation of PPARα also accelerates reverse cholesterol transport (RCT) via increased expression of ABCA1 and ABCG1 transporters involved in cholesterol efflux from macrophages [29, 40].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [40]
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630 · cited 1×
“, and this led to the suggestion that PPAR-activators may modulate foam-cell formation, a known atherogenic process characterized by cholesteryl-ester-droplet accumulation in the cytoplasm of macrophage”
BackgroundThe peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899 · cited 1×
“Both PPAR-α and PPAR-γ are expressed in fully-differentiated human macrophages where they regulate genes implicated in the inflammatory response, modulate macrophage differentiation and promote TNF-α/IFN-γ–induced apoptosi”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“We treated these cells with either the PPAR-α ligand Wy14643 or the PPAR-γ ligand rosiglitazone at concentrations of 2–3 times their EC 50 values (Wy14643 EC 50 for human PPAR-αe25 μM and rosiglitazone EC 50 for human PPAR-γe43 nM”
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 1×
“Moreover, PPAR-α activation results in the transcriptional induction of CD36 expression in macrophage”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 1×
“The stimulatory role of PPAR-α activators on hepatic HDL production and apoAI expression is well-documente”
BackgroundSelf-citationMutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
An oxysterol signalling pathway mediated by the nuclear receptor LXRα
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., & Mangelsdorf, D. J. (1996) · Nature · doi:10.1038/383728a0 · Cited by 1,591 · cited 1×
“We also show that both PPAR-α and PPAR-γ activators induce ABCA1 expression, possibly through their inductive effects on expression of LXR-α, a nuclear receptor activated by oxysterol”
Background
Cited by
Items 501–600 of 1,000
Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists
Bassaganya-Riera, J., Guri, A. J., & Hontecillas, R. (2010) · Journal of Obesity · doi:10.1155/2011/897894 · Cited by 42
Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies
Heald, M., & Cawthorne, M. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_2 · Cited by 43
“Moreover, by increasing the expression of the HDL receptor CLA-1/SR-BI (Chinetti et al. 2000) and the cholesterol transporter ABCA1 (Chinetti et al. 2001), they promote cholesterol efflux from the macrophages.”
BackgroundAdipose tissue infiltration in normal-weight subjects and its impact on metabolic function
Moreno‐Indias, I., Oliva‐Olivera, W., Omiste, A., Castellano‐Castillo, D., Lhamyani, S., Camargo, A., & Tinahones, F. J. (2016) · Translational research · doi:10.1016/j.trsl.2016.01.002 · Cited by 44
“In this line, PPARgamma has a regulatory role in the first steps of the reverse-cholesterol-transport pathway through activation of ATP-Binding Cassette Transporter, sub-family A, member 1 (ABCA1)-mediated cholesterol efflux in human macrophages.(50) Thus, the HDL-cholesterol level seems to be themost determinant fact…”
BackgroundNissilä, E., Hakala, P., Leskinen, K., Roig, A., Syed, S., van Kessel, K. P. M., Metso, J., de Haas, C. J. C., Saavalainen, P., Meri, S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02701 · Cited by 40
Liu, L., Tan, L., Yao, J., & Yang, L. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10987 · Cited by 44
Weldon, S., Mitchell, S., Kelleher, D. P., Gibney, M. J., & Roche, H. M. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.02.007 · Cited by 44
Bruschi, F. V., Claudel, T., Tardelli, M., Starlinger, P., Marra, F., & Trauner, M. (2019) · Hepatology Communications · doi:10.1002/hep4.1395 · Cited by 38
“(24) and Chinetti and coworkers(30) reported the tight connection between PPARγ and LXR axes in controlling ABCA1 expression in human macrophages.”
BackgroundInfluentialMandolini, C., Santovito, D., Marcantonio, P., Buttitta, F., Bucci, M., Ucchino, S., Mezzetti, A., & Cipollone, F. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.09.005 · Cited by 40
“subsequent cholesterol ester accumulation in macrophages, and increase the risk of developing cardiovascular diseases [7].”
BackgroundCilostazol enhances macrophage reverse cholesterol transport in vitro and in vivo
Nakaya, K., Ayaori, M., Uto‐Kondo, H., Hisada, T., Ogura, M., Yakushiji, E., Takiguchi, S., Terao, Y., Ozasa, H., Sasaki, M., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.07.024 · Cited by 39
Gray, E., Ginty, M., Kemp, K. C., Scolding, N. J., & Wilkins, A. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07637.x · Cited by 42
Nuclear receptors, the aryl hydrocarbon receptor, and macrophage function
Lamorte, S., Shinde, R. S., & McGaha, T. L. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100942 · Cited by 38
“Excess oxidized lipids activate PPARγ, which participates in the control of cholesterol efflux through a transcriptional cascade involving first LXRα expression and, consequently, LXRα-induced ABCA1 expression (51, 52).”
BackgroundNagatake, T., Shibata, Y., Morimoto, S., Node, E., Sawane, K., Hirata, S., Adachi, J., Abe, Y., Isoyama, J., Saika, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89707-1 · Cited by 42
Targeting PPARs for therapy of atherosclerosis: A review
Miao, M., Wang, X., Liu, T., Li, Y., Yu, W., Yang, T.-M., & Guo, S. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125008 · Cited by 45
ATP binding cassette transporter A1 - key roles in cellular lipid transport and atherosclerosis
Srivastava, N. (2002) · Molecular and Cellular Biochemistry · doi:10.1023/a:1016506221047 · Cited by 40
CD36, insulin resistance, and coronary heart disease
Aitman, T. J. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04149-0 · Cited by 40
Melatonin inhibits bladder tumorigenesis by suppressing PPARγ/ENO1-mediated glycolysis
Shen, D., Deng, Z., Liu, W., Zhou, F., Fang, Y., Shan, D., Wang, G., Qian, K., Yu, M., Zhang, Y., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05770-8 · Cited by 40
Jia, L., Zhang, N., Xu, Y., Chen, W., Zhu, M.-L., Song, N., Ren, L., Cao, H., Wang, J., & Yang, G. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2016.01.001 · Cited by 37
Peroxisome proliferator-activated receptors
Ziouzenkova, O., Perrey, S., Marx, N., Bacqueville, D., & Plutzky, J. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0063-x · Cited by 37
Retinoid X Receptor Heterodimer Variants and Cardiovascular Risk Factors
Nohara, A., Kobayashi, J., & Mabuchi, H. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.no786 · Cited by 41
Effects of Pravastatin on the Expression of ATP-Binding Cassette Transporter A1
Ando, H., Tsuruoka, S., Yamamoto, H., Takamura, T., Kaneko, S., & Fujimura, A. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068213 · Cited by 42
Carpenter, K. L. H., Challis, I. R., & Arends, M. J. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01007-x · Cited by 37
Hossain, G. S., Lynn, E. G., Maclean, K. N., Zhou, J., Dickhout, J. G., Lhoták, Š., Trigatti, B. L., Capone, J. P., Rho, J., Tang, D., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000134 · Cited by 37
Lipid-lowering fibrates extend C. elegans lifespan in a NHR-49/PPARalpha-dependent manner
Brandstädt, S. M., Schmeißer, K., Zarse, K., & Ristow, M. (2013) · Aging · doi:10.18632/aging.100548 · Cited by 41
Wang, L., Ladurner, A., Latkolik, S. L., Schwaiger, S., Linder, T., Hošek, J., Palme, V., Schilcher, N., Polanský, O., Heiß, E. H., et al. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.6b00227 · Cited by 37
Kong, R., Luo, H., Wang, N., Li, J., Xu, S., Chen, K., Feng, J., Wu, L., Li, S., Liu, T., et al. (2018) · PPAR Research · doi:10.1155/2018/6079101 · Cited by 36
Wang, L., Eftekhari, P., Schachner, D., Ignatova, I. D., Palme, V., Schilcher, N., Ladurner, A., Heiß, E. H., Stangl, H., Dirsch, V. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29281-1 · Cited by 36
Srivastava, R. A. K. (2002) · Molecular and Cellular Biochemistry · doi:10.1023/a:1020604610873 · Cited by 38
“gene expression in macrophages [36], but it is not known whether fenofibrate regulates the hepatic ABCA1 mRNA.”
BackgroundWu, C., Chen, R., Liu, M., Liu, D., Li, X., Wang, S., Niu, S., Guo, P., & Lin, W. (2015) · Marine Drugs · doi:10.3390/md13106352 · Cited by 37
Tan, H. C., Tai, E. S., Sviridov, D., Nestel, P. J., Ng, C. L. W., Chan, E., Teo, Y., & Wai, D. C. H. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.06.016 · Cited by 38
Novel Peroxisome Proliferator Activated Receptor–α Agonists
Fruchart, J. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.08.012 · Cited by 36
Self-citationAgassandian, M., Miakotina, O. L., Andrews, M., Mathur, S. N., & Mallampalli, R. K. (2007) · Biochemical Journal · doi:10.1042/bj20061364 · Cited by 36
ABCG1 mediated oxidized LDL-derived oxysterol efflux from macrophages
Xu, M., Zhou, H., Tan, K. C. B., Guo, R., Shiu, S. W. M., & Wong, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.152 · Cited by 38
Lipid and lipoprotein metabolism in microglia: Alzheimer’s disease mechanisms and interventions
Sprenger, K. G., Lietzke, E. E., Melchior, J. T., & Bruce, K. D. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100872 · Cited by 42
“ApoA1 promotes the efflux of cholesterol and PLs through the interaction with ABCA1 (110).”
Novel concepts in HDL pharmacology
Remaley, A. T., Norata, G. D., & Catapano, A. L. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu141 · Cited by 36
Self-citationMangum, L. C., Hou, X., Borazjani, A., Lee, J. H., Ross, M. K., & Crow, J. A. (2018) · Biochemical Journal · doi:10.1042/bcj20180008 · Cited by 36
Common ABCA1 variants, HDL levels, and cellular cholesterol efflux in subjects with familial low HDL
Soro‐Paavonen, A., Naukkarinen, J., Lee‐Rueckert, M., Watanabe, H., Rantala, E., Söderlund, S., Hiukka, A., Kovanen, P. T., Jauhiainen, M., Peltonen, L., et al. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p600012-jlr200 · Cited by 39
Procházka, L., Koudelka, Š., Dong, L., Štursa, J., Goodwin, J., Neča, J., Slavík, J., Cigánek, M., Mašek, J., Kľučková, K., et al. (2013) · APOPTOSIS · doi:10.1007/s10495-012-0795-1 · Cited by 35
“This indicates that the ABCA1 protein may be involved, since it is known to remove cholesterol from cells in the process of reverse cholesterol transport [45].”
Upregulation of surfactant synthesis triggers ABCA1-mediated basolateral phospholipid efflux
Zhou, J., You, Y., Ryan, A. J., & Mallampalli, R. K. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400179-jlr200 · Cited by 35
Toyoda, T., Kamei, Y., Kato, H., Sugita, S., Takeya, M., Suganami, T., & Ogawa, Y. (2008) · Obesity · doi:10.1038/oby.2008.62 · Cited by 43
Alassane‐Kpembi, I., Pinton, P., Hupé, J.-F., Neves, M., Lippi, Y., Combes, S., Castex, M., & Oswald, I. P. (2018) · Toxins · doi:10.3390/toxins10050199 · Cited by 40
“As a consequence, deficiency in PPAR signaling is pivotal for the establishment of the foam cells of atherosclerotic lesions [37].”
BackgroundChen, C., Shyue, S., Ching, L., Su, K., Wu, Y.-L., Kou, Y. R., Chiang, A.-N., Pan, C.-C., & Lee, T. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.08.014 · Cited by 35
“These findings suggest that wogonin attenuates cholesterol accumulation by escalating ABCA1-dependent cholesterol efflux during the transformation of foam cells, which is in agreement with previous studies finding that induction of ABCA1 contributes to the suppression of lipid accumulation in foam cells [45,46].”
ResultChen, W., Penumetcha, M., Santanam, N., Liu, Y.-G., Garelnabi, M., & Parthasarathy, S. (2005) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.03.005 · Cited by 39
Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients
Wang, J., Bao, Y., Hu, C., Zhang, R., Wang, C., Lu, J., Jia, W., & Xiang, K. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00744.x · Cited by 35
Bahia, L., Kraemer‐Aguiar, L. G., Villela, N. R., Bottino, D. A., Godoy‐Matos, A. F., Geloneze, B., Tambascia, M. A., & Bouskela, E. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.09.003 · Cited by 38
Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism
Rader, D. J. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03384-2 · Cited by 33
ATP Binding Cassette Transporters
Dufort, L., & Chimini, G. (2007) · Wiley eBooks · doi:10.1002/9783527625178.ch5 · Cited by 34
Guo, C., Zhao, X., Ma, R., Zhu, L., Chen, Y., Yang, Z., Cai, Z., Sun, Z., & Li, Y. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.163430 · Cited by 38
The role of the liver X receptor in chronic obstructive pulmonary disease
Higham, A., Lea, S., Plumb, J., Maschera, B., Simpson, K. D., Ray, D. W., & Singh, D. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-106 · Cited by 33
Chang, G., Chen, P., Hou, P., & Mao, F. C. (2015) · PubMed Central · Cited by 41
Yang, Z., Gordon, S. M., Sviridov, D. O., Wang, S., Danner, R. L., Pryor, M., Vaisman, B. L., Shichijo, Y., Doisaki, N., & Remaley, A. T. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.017 · Cited by 36
Self-citationLin, J., Liu, Q., Zhang, H., Huang, X., Zhang, R., Chen, S., Wang, X., Yu, B., & Hou, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19657 · Cited by 34
Choi, J. Y., Ryu, J., Kim, H. J., Song, J. W., Jeon, J. H., Lee, D., Oh, D. J., Gweon, D., Oh, W., Yoo, H., et al. (2017) · Theranostics · doi:10.7150/thno.20885 · Cited by 35
“PPARγ activation upregulates the regulators of cholesterol efflux in macrophages [3, 4] and reduces inflammation in atheroma by inhibiting nuclear factor-kappa B activity [4-8], this pathway could be an attractive target for treating atherosclerosis.”
Astrocytic dysfunction induced by ABCA1 deficiency causes optic neuropathy
Shinozaki, Y., Leung, A., Namekata, K., Saitoh, S., Nguyen, H. B., Takeda, A., Danjo, Y., Morizawa, Y. M., Shigetomi, E., Sano, F., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq1081 · Cited by 35
Buono, C., Li, Y., Waldo, S. W., & Kruth, H. S. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700170-jlr200 · Cited by 32
Puttabyatappa, M., VandeVoort, C. A., & Chaffin, C. L. (2010) · Endocrinology · doi:10.1210/en.2010-0698 · Cited by 35
R??os-V??zquez, R., Marzoa‐Rivas, R., Gil-Ortega, I., & Kaski, J. C. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606040-00003 · Cited by 36
Ho, T., Yang, Y., Chen, S., Kuo, P., Sytwu, H., Cheng, H.-C., & Tsao, Y. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.08.004 · Cited by 32
Fibrates and coronary risk reduction
Steiner, G. A. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.04.002 · Cited by 38
Liu, J., Lin, S., Ho, Y., Pan, S., Hung, L.-F., Tsai, S., Lin, J., & Liang, Y. (2003) · Molecular Carcinogenesis · doi:10.1002/mc.10119 · Cited by 33
Bossé, Y., Pascot, A., Dumont, M., Brochu, M., Prud’homme, D., Bergeron, J., Després, J., & Vohl, M. (2002) · Genetics in Medicine · doi:10.1097/00125817-200207000-00010 · Cited by 38
Vanherle, S., Jorissen, W., Dierckx, T., Loix, M., Grajchen, E., Mingneau, F., Guns, J., Gervois, P., Lambrichts, I., Dehairs, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111591 · Cited by 31
Self-citationMehta, N. U., Grijalva, V. R., Hama, S. Y., Wagner, A. C., Navab, M., Fogelman, A. M., & Reddy, S. T. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306991 · Cited by 33
Fotschki, B., Juśkiewicz, J., Jurgoński, A., Rigby, N. M., Sójka, M., Kołodziejczyk, K., Mackie, A. R., & Zduńczyk, Z. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.03.004 · Cited by 35
“This receptor regulates intra- and extracellular lipid metabolism and stimulates reverse transport of cholesterol [57], which is essential for BA synthesis.”
BackgroundGopal, K., Nagarajan, P., Jedy, J., Raj, A. T., Kalai Gnanaselvi, S., Jahan, P., Sharma, Y., Shankar, E. M., & Kumar, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067098 · Cited by 32
“Experimental evidence suggest that both, PPAR-c and PPAR-a are expressed in human macrophages where they exert anti-inflammatory effects [28,29].”
BackgroundLuoma, P. V. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0515-5 · Cited by 37
Chinetti, G., & Staels, B. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.01.009 · Cited by 40
Self-citationHou, M., Xia, M., Zhu, H., Wang, Q., Li, Y., Xiao, Y., Zhao, T., Tang, Z., Ma, J., & Ling, W. (2006) · Cell Biochemistry and Function · doi:10.1002/cbf.1374 · Cited by 37
Llaverías, G., Lacasa, D., Viñals, M., Vázquez‐Carrera, M., Sánchez, R. M., Laguna, J. C., & Alegret, M. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.03.009 · Cited by 33
Bultel, S., Helin, L., Barthelemy-Clavey, V., Chinetti, G., Rigamonti, E., Colin, M., Fruchart, J., Staels, B., & Lestavel, S. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.175042 · Cited by 35
Self-citationCalkin, A. C., & Allen, T. J. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606010-00003 · Cited by 35
Novel insulin sensitizers: pharmacogenomic aspects
Otto, C., Lehrke, M., & Göke, B. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.1.99 · Cited by 33
Tikellis, C., Jandeleit-Dahm, K. A. M., Sheehy, K., Murphy, A. J., Chin-Dusting, J. P. F., Kling, D., ŠEBÖKOVÁ, E., Cooper, M. E., Mizrahi, J. L., & Woollard, K. J. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.10.038 · Cited by 35
Intestine-Specific Regulation of PPARα Gene Transcription by Liver X Receptors
Colin, S., Bourguignon, E., Boullay, A.-B., Tousaint, J.-J., Huet, S., Caira, F., Staels, B., Lestavel, S., Lobaccaro, J. A., & Delerive, P. (2008) · Endocrinology · doi:10.1210/en.2008-0637 · Cited by 35
Self-citationPeroxisome Proliferator-Activated Receptors and Atherosclerosis
Šoškić, S., Dobutović, B., Sudar-Milovanovic, E. M., Obradovic, M. M., Nikolić, D., Zarić, B. L., Stojanović, S. Đ., Stokić, E., Mikhailidis, D. P., & Isenović, E. R. (2011) · Angiology · doi:10.1177/0003319711401012 · Cited by 33
“In macrophages, PPARg agonists have been demonstrated to both increase PPARg expression and inhibit MMP synthesis, which contributes to their inhibitory effects on VSMC proliferation.94 In addition, PPARg ligands are known to inhibit monocyte/macrophage production of other inflammatory cytokines, such as IL-6, IL-1b,…”
BackgroundMicroRNAs and the response to injury in atherosclerosis
Natarelli, L., & Schober, A. (2015) · Hämostaseologie · doi:10.5482/hamo-14-10-0051 · Cited by 33
Nakano, Y., Uchiyama, M., Arima, T., Nagasaka, S., Igarashi, T., Shimizu, A., & Takahashi, H. (2018) · Molecules · doi:10.3390/molecules24010114 · Cited by 31
Function and Dysfunction of Complement Factor H During Formation of Lipid-Rich Deposits
Meri, S., & Haapasalo, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.611830 · Cited by 33
Alveolar macrophages in pulmonary alveolar proteinosis: origin, function, and therapeutic strategies
Huang, X., Cao, M., & Xiao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1195988 · Cited by 37
PPAR Agonists and Cardiovascular Disease in Diabetes
Calkin, A. C., & Thomas, M. C. (2008) · PPAR Research · doi:10.1155/2008/245410 · Cited by 32
“PPARγ agonists also stimulate reverse cholesterol transport [50, 51] and have beneficial effects on the low HDL cholesterol levels and elevated triglyceride levels that characterize diabetic dyslipidaemia.”
Mécanismes d’action des statines et des fibrates
Duriez, P. (2003) · Therapies · doi:10.2515/therapie:2003002 · Cited by 40
Sesamin Enhances Cholesterol Efflux in RAW264.7 Macrophages
Liu, N., Wu, C., Sun, L., Zheng, J., & Guo, P. (2014) · Molecules · doi:10.3390/molecules19067516 · Cited by 32
Jossic-Corcos, C. L., Duclos, S., Ramirez, L. C., Zaghini, I., Chevillard, G., Martin, P. G. P., Pineau, T., & Bournot, P. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2004.04.004 · Cited by 31
Srivastava, R. A. K., & He, S. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0573-8 · Cited by 31
Tian, J., Liu, Y., Liu, Y., Chen, K., & Lyu, S. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9080869 · Cited by 32
Schuster, H., Fagerberg, B., Edwards, S., Halmos, T., Łopatyński, J., Stender, S., Birketvedt, G. S., Tonstad, S., Gause‐Nilsson, I. A. M., Halldórsdóttir, S., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.05.029 · Cited by 32
The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC)
Narrandes, S., Huang, S., Murphy, L. C., & Xu, W. W. (2018) · BMC Cancer · doi:10.1186/s12885-017-3939-4 · Cited by 32
Wouters, E., Grajchen, E., Jorissen, W., Dierckx, T., Wetzels, S., Loix, M., Tulleners, M. P., Staels, B., Stinissen, P., Haidar, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239329 · Cited by 31
Self-citationTherapeutic strategies to deplete macrophages in atherosclerotic plaques
Meyer, I. D., Martinet, W., & Meyer, G. R. Y. D. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04211.x · Cited by 35
StAR Overexpression Decreases Serum and Tissue Lipids in Apolipoprotein E‐deficient Mice
Ning, Y., Xu, L., Ren, S., Pandak, W. M., Chen, S., & Yin, L. (2009) · Lipids · doi:10.1007/s11745-009-3299-1 · Cited by 33
Li, J., Li, F., & Zhao, A. Z. (2006) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2006.09.003 · Cited by 44
Direct antiatherosclerotic effects of PPAR agonists
Jandeleit-Dahm, K. A. M., Calkin, A. C., Tikellis, C., & Thomas, M. C. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32831f1b18 · Cited by 31
Malek, M. A., Hoang, M.-H., Jia, Y., Lee, J. H., Jun, H. J., Lee, D., Lee, H. J., Lee, C., Lee, M. K., Hwang, B. Y., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.12.020 · Cited by 34
“It is well documented that PPAR agonists increase the expression of ATPbinding cassette A1 (ABCA1), thereby enhancing the biogenesis of HDL via a process that involves LXRs, particularly LXRa [7].”
BackgroundNamgaladze, D., Kemmerer, M., von Knethen, A., & Brüne, B. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt073 · Cited by 33
Mashurabad, P. C., Palsa, K., Palika, R., Ghosh, S., Nair, M. K., & Pullakhandam, R. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.11.002 · Cited by 32
Ho, M.-M., Manughian-Peter, A. O., Spivia, W. R., Taylor, A., & Fraser, D. A. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.019 · Cited by 31
Regulation of HDL Genes: Transcriptional, Posttranscriptional, and Posttranslational
Kardassis, D., Gafencu, A. V., Zannis, V. I., & Dávalos, A. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_3 · Cited by 31
Rodrigues, G. A., Maurier, F., Shurland, D., McLaughlin, A. P., Luhrs, K. A., Throo, E., Delalonde-Delaunay, L., Pallares, D., Schweighoffer, F., & Donello, J. E. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5715 · Cited by 33
Nassar, B. A., Rockwood, K. J., Kirkland, S., Ransom, T. P. P., Darvesh, S., MacPherson, K. M., Johnstone, D. E., O’Neill, B. J., Bata, I. R., Andreou, P., et al. (2005) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2005.10.002 · Cited by 30
The Cholesterol Mobilizing Transporter ABCA1 as a New Therapeutic Target for Cardiovascular Disease
Oram, J. F. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(02)00159-7 · Cited by 32
Vaziri, Z., Saleki, K., Aram, C., Alijanizadeh, P., Pourahmad, R., Azadmehr, A., & Ziaei, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115686 · Cited by 31
Metadata
- Authors
- Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H. B., Fruchart, J.-C., Clavey, V., & Staels, B.
- Affiliations
- Inserm (FR)
- National Institutes of Health (US)
- Sanofi (France) (FR)
- Corresponding author
- Staels, Bart
- Venue
- Nature Medicine
- Published
- 2001-01
- Volume
- 7
- Issue
- 1
- Pages
- 53-58
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1524478189
- Cited by
- 1,170
- References
- 39
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 31 · 2023: 41 · 2022: 25 · 2021: 28 · 2020: 30 · 2019: 20 · 2018: 29 · 2017: 31 · 2016: 38 · 2015: 33 · 2014: 50 · 2013: 37 · 2012: 38
- FWCI
- 99.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PPARα, PPARγ, ABCA1, cholesterol efflux, foam cells, macrophages, reverse cholesterol transport, liver X receptor alpha, apolipoprotein A-I, Tangier disease, acetylated LDL, CD36, THP-1 macrophages
- MeSH terms
- Base Sequence, Biological Transport, Cells, Cultured, Cholesterol, Foam Cells, Humans, Transcription Factors, DNA Primers, Receptors, Cytoplasmic and Nuclear, ATP-Binding Cassette Transporters, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.